It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress.
The abstracts ‘Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma‘ (ABSTRACT NUMBER: 179) and ‘Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma‘ (ABSTRACT NUMBER: 133) were presented at the virtual 62nd ASH Annual Meeting and Exposition, 5-8 December, 2020.
- Please could you give an overview of MEDI2228 and its mechanism of action? (0:07)
- What have the findings of the first-in human study taught us about the efficacy and safety of MEDI2228 in patients with relapsed/refractory multiple myeloma? (1:08)
- What is the rationale for the use of anti-BCMA CAR-T cells in the treatment of patients with relapsed/refractory multiple myeloma? (3:33)
- On the basis of data from Lummicar-2, how does CT053 CAR-T cell therapy compare with other CAR-T cell therapies in development for multiple myeloma? (4:46)
- What were your personal highlights of this year’s ASH virtual congress? (6:53)
Speaker Disclosures: Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio; Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca, and (with personal payment) Oncopeptides, Beigene and Antagene.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ASH 2020.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!